PCSK9 Polyklonaler Antikörper

• Featured Product
• KD/KO Validated

PCSK9 Polyklonal Antikörper für IHC, WB, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Ratte und mehr (1)

Anwendung

WB, IP, IHC, IF, ChIP, ELISA

Konjugation

Unkonjugiert

Publikationen

39

Rezensionen (1)

Kat-Nr. : 55206-1-AP

Synonyme

FH3, HCHOLA3, LDLCQ1, NARC 1, NARC1, PC9, PCSK9, Proprotein convertase 9

---

Galerie der Validierungsdaten

• 

  WB analysis using 55206-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 55206-1-AP (PCSK9 antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 55206-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 55206-1-AP (PCSK9 antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human colon cancer using 55206-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 55206-1-AP (PCSK9 antibody) at dilution of 1:500 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human colon cancer using 55206-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 55206-1-AP (PCSK9 antibody) at dilution of 1:500 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human colon cancer using 55206-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 55206-1-AP (PCSK9 antibody) at dilution of 1:500 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: COLO 320-Zellen, HepG2-Zellen, SMMC-7721-Zellen
• Erfolgreiche Detektion in IHC: humanes Kolonkarzinomgewebe; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:500-1:3000
• Immunhistochemie (IHC): IHC : 1:250-1:1000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• KD/KO: See 7 publications below
• WB: See 33 publications below
• IHC: See 13 publications below
• IF: See 4 publications below
• IP: See 1 publications below
• ChIP: See 1 publications below

Produktinformation

55206-1-AP bindet in WB, IP, IHC, IF, ChIP, ELISA PCSK9 und zeigt Reaktivität mit human, Ratten

• Getestete Reaktivität: human, Ratte
• In Publikationen genannte Reaktivität: human, hamster, Ratte
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: Peptid
• Vollständiger Name: proprotein convertase subtilisin/kexin type 9
• Berechnetes Molekulargewicht: 74 kDa
• Beobachtetes Molekulargewicht: 58-62 kDa, 72-78 kDa
• GenBank-Zugangsnummer: NM_174936
• Gene symbol: PCSK9
• Gene ID (NCBI): 255738
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). PCSK9 is expressed in the kidney and lung. It is synthesized as a 72 kDa immature precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum to generate a 63 kDa mature protein. The cleaved N-terminal fragment remains associated with the mature protein and is necessary for its secretion, allowing it to circulate in the blood. The ability of PCSK9 to regulate a diverse group of cell-surface proteins hinted that it might also be able to influence additional membrane proteins that are important in anti-tumour immune responses. Targeting PCSK9 to treat cancer is also attractive because two neutralizing antibodies against it, evolocumab and alirocumab, have already been approved for human clinical use to lower cholesterol levels. (PMID: 30522786, PMID: 22493497)

Publikationen

Species	Application	Title
human	WB	Nature; Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.; Authors - Xinjian Liu ; KO Validated
	WB,IHC,IF	J Nanobiotechnology; Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy; Authors - Zhenxian Li
human,hamster	WB	Biomed Pharmacother; Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases; Authors - Hui-Hui Guo
human	IHC	Front Immunol; PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer; Authors - Xiang Gao
human	WB	Int J Mol Sci; Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity; Authors - Po-Wei Chen
rat,human	WB,IHC,IF	Int J Mol Sci; Renal Ischemia/Reperfusion Early Induces Myostatin and PCSK9 Expression in Rat Kidneys and HK-2 Cells.; Authors - Chiara Barisione

Rezensionen

The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.

---

FH

Malak (Verified Customer) (11-30-2020)

The antibody works very well in IHC staining especially at pH6 and 1/100 dilution

• Applications: Immunohistochemistry
• Primary Antibody Dilution: 1/100
• Cell Tissue Type: Hepatic tissue